As reported by the National Health Executive, urgent referrals for suspected bowel cancer fell well below expected levels in 2024/25, following the widespread use of faecal immunochemical testing to support decision making in primary care
Figures show there were around 140,000 fewer urgent referrals than projected for the year, a reduction of 22% compared with the pre pandemic trend. This change occurred without a fall in cancer detection rates.
The reduction reflects the role of FIT in helping GPs assess risk before referral. By identifying which patients are more likely to require further investigation, the test supports more targeted use of urgent diagnostic pathways while allowing low risk patients to be reassured.
The faecal immunochemical test involves a simple stool sample taken at home and checks for traces of blood, which can be an early sign of bowel cancer. The approach is recommended by NICE for use in primary care.
Bowel cancer, which affects the colon and rectum, remains the second biggest cause of cancer death in the UK.
